Shares of Haemonetics Corporation (NYSE: HAE) are soaring 16.32% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results that significantly surpassed analyst expectations. The medical technology company, specializing in blood and plasma supplies and services, reported strong earnings and raised its full-year guidance, sparking investor enthusiasm.

Haemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. While this represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business, the company's organic revenue excluding CSL increased by an impressive 9.4% for the quarter. The adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99 and marking a 13.39% increase from the $1.12 per share reported in the same quarter last year.

In response to the strong performance, Haemonetics raised the lower end of its fiscal 2026 adjusted EPS guidance to $4.80 to $5.00, up from the previous range of $4.70 to $5.00. This upward revision in guidance signals management's confidence in the company's future performance and has further fueled the stock's pre-market rally. The significant earnings beat and improved outlook appear to be the primary drivers behind the stock's substantial gain, as investors reassess the company's growth prospects in the medical technology sector.